Impact of a novel contrast reduction system on contrast savings in coronary angiography - The DyeVert randomised controlled trial.
| Author | |
|---|---|
| Abstract |
:
The most prominent procedure-related and thus modifiable risk factor for contrast-induced acute kidney injury is contrast media (CM) volume. The DyeVert™ system has been designed to reduce the amount of CM. The primary objective of this randomised controlled trial was thus to examine whether the novel DyeVert™ contrast reduction system (Osprey Medical Inc., Minnetonka, MN, USA) leads to a reduction in CM volume in patients undergoing diagnostic coronary angiography. |
| Year of Publication |
:
2018
|
| Journal |
:
International journal of cardiology
|
| Date Published |
:
2018
|
| ISSN Number |
:
0167-5273
|
| DOI |
:
10.1016/j.ijcard.2017.12.107
|
| Short Title |
:
Int J Cardiol
|
| Download citation |
